National feature spotlights TumorSight™ Viz's clinical use at Mercy Cedar Rapids and initiative with NVIDIA advancing AI-powered precision breast cancer care CHICAGO, Oct. 27, 2025 /PRNewswire/ -- ...
Celcuity's phase 3 VIKTORIA-1 trial showed that gedatolisib significantly improved progression-free survival in PIK3CA wild-type HR+/HER2-advanced breast cancer patients. NDA submission for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback